Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

UTRUSTANDE: Utforska kombinerade lokala och systemiska tillvägagångssätt i hjärnmetastaser: en randomiserad multikohort-fas II-studie som utvärderar initialt svar på systemisk terapi och efterföljande integrering av stereootaktisk strålkirurgi hos patienter med hjärnmetastaser med låg risk och aktiva centrala nervsystemet

5 oktober 2026 uppdaterad av: M.D. Anderson Cancer Center

Utrop: Utforska kombinerade lokala och systemiska tillvägagångssätt i hjärnmetastaser: en randomiserad fas II-studie med flera kohorter som utvärderar initialt svar på systemisk terapi och efterföljande integration av stereootaktisk strålkirurgi hos patienter med hjärnmetastaser med låg risk och aktiv systemisk terapi i centrala nervsystemet

To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy.

To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

Primary Objectives:

To assess whether cSRS improves CNS progression-free survival (CNS-PFS) in patients with BM who have a PR or SD with upfront systemic therapy.

To assess whether SRS to all BM not in CR (cSRS + pdSRS) versus only progressing lesions (pdSRS) improves CNS-PFS in patients with CNS progression on upfront systemic therapy.

Secondary Objectives:

To report the rate and degree of response of BM to systemic therapy by specific regimen and histology.

To report adverse neurologic events that occur with BM treated with upfront systemic therapy and differences in these events between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To evaluate rates of LMD in all patients managed with upfront systemic therapy and differences in LMD rates between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To evaluate neurocognitive changes in patients treated with upfront systemic therapy for BMand differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

To perform inference on overall survival as estimated by the Kaplan-Meier estimator in patients treated with upfront systemic therapy for BM and differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).

Exploratory Objectives:

To correlate imaging biomarkers with outcomes of BM treated with systemic therapy.

To correlate volumetric assessment of lesion response to conventional assessment by mRECIST 1.1.

To explore ML as a tool to predict outcomes of BM treatment based on disease specific, clinical, and lesion specific features.

To explore the association of circulating bioanalytes with up front systemic therapy for BM and subsequent downstream management strategies (i.e. cSRS).

Studietyp

Interventionell

Inskrivning (Beräknad)

316

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • The University of Texas MD Anderson Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Thomas H Beckham, MD,PHD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Evaluation by a brain metastasis multidisciplinary team (BM-MDT) consisting of a medical oncologist (can be the patient's primary medical oncologist), a radiation oncologist who regularly performs SRS, and a neurosurgeon. This evaluation can take place in clinic or during a multidisciplinary conference.
  3. Life expectancy > 6 months as estimated by BM-MDT.
  4. BM-MDT agreement that the planned systemic therapy regimen may provide intracranial benefit (SD, PR, or CR in the CNS).
  5. BM-MDT agreement that the patient's BM does not require immediate local therapy (surgery and/or radiation therapy); i.e. it is judged to be safe to omit local therapy as initial BM management.
  6. The patient's BM are amenable to SRS as initial local therapy as determined by BM-MDT.
  7. Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
  8. Histologically confirmed metastatic cancer with at least one measurable metastasis in the brain (≥ 5 mm).
  9. At least one measurable intracranial target lesion which was not previously treated with SRS. Regrowth in a cavity of previously excised lesion will not qualify as a measurable lesion. Growth or change in a lesion previously irradiated will not qualify as a measurable lesion.
  10. Prior SRS and prior excision of BM is permitted if other measurable non irradiated lesions as described in #9 remain.
  11. The resection cavity of excised BM must have received appropriate radiation therapy (pre or post operative SRS, brachytherapy) or have been observed for >6 months after resection without evidence of local cavity recurrence.
  12. Subjects must be free of neurologic signs and symptoms related to metastatic brain lesions either without systemic corticosteroids or requiring ≤ 2 mg dexamethasone daily for symptom resolution.
  13. ECOG performance status ≤ 1.
  14. Documented agreement by the patient's primary medical oncologist with the appropriateness of planned SST regimen.
  15. This study will allow non-English speaking subjects to be enrolled. Verbal Translation Preparative Sheet (VTPS) will be used if a translated consent form is not available in the subject's language. The consent form will be translated into the language of the subject after 2 or more occurrences. This will apply to any MD Anderson patient.

Exclusion Criteria:

  1. History of known leptomeningeal involvement (radiographic or cytological).
  2. Small cell lung cancer, lymphoma, or leukemia histology.
  3. Non-small cell lung cancer histology with targetable oncogenic driver mutation with planned initiation of highly CNS active targeted therapy (eg osimertinib, brigatinib, alectinib, or lorlatinib).
  4. Subjects previously treated with WBRT.
  5. Any intact BM size > 3 cm. After surgical excision and appropriate radiation therapy to the cavity, patients may enroll if additional eligible lesions are present.
  6. Prior disease progression on one or more of the agents comprising SST.
  7. Exposure to one or more agents comprising SST within the last 30 days.
  8. Prior unacceptable toxicity during treatment with one or more agents comprising SST.
  9. Subjects with a major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled.
  10. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful treatment of superficial bladder cancer, in situ cervical cancer, ductal carcinoma in situ, or other in-situ cancers. Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
  11. Skin Cancer Exclusion: Please note that localized cutaneous basal cell carcinoma and squamous cell carcinoma is not an exclusion criterion regardless of treatment status. Biopsy proven metastatic disease from these histologies is an exclusion criterion if this constitutes a second cancer.
  12. Patient weight >450 pounds.
  13. Patient had prior SRS to any intracranial lesion <15mm from a metastasis on the screening MRI. Prior MRIs and DICOMs will be used to make this determination.
  14. Patient unable to receive a brain MRI (implanted metal devices or foreign bodies) or MRI contrast.
  15. Any BM with a significant hemorrhagic component (defined as MRI T1 intrinsic hyperintensity comprising ≥ 25% of maximal lesion diameter).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: cSRS PR or SD

Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimentell: a-pdSR CNS PD

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimentell: b-PDC CNS PD

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimentell: SST treated SD or PR patients to receive cSRS/ ongoing observation

Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Experimentell: SST treated PD patients to pdSRS / pdSRS+cSRS

At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS.

Participants will receive systemic therapy as a standard of care therapeutic option

Participants will receive systemic therapy as a standard of care therapeutic option

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety and Adverse Events (AEs).
Tidsram: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Thomas H Beckham, MD,PHD, M.D. Anderson Cancer Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 februari 2025

Primärt slutförande (Beräknad)

30 september 2028

Avslutad studie (Beräknad)

30 september 2030

Studieregistreringsdatum

Först inskickad

17 oktober 2024

Först inskickad som uppfyllde QC-kriterierna

17 oktober 2024

Första postat (Faktisk)

18 oktober 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera